サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1747452

犬の拡張型心筋症（DCM）治療薬の世界市場：治療アプローチ別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年

Global Canine Dilated Cardiomyopathy (DCM) Drugs Market Assessment, By Therapeutic Approach, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 229 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.80円
犬の拡張型心筋症（DCM）治療薬の世界市場：治療アプローチ別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年
出版日: 2025年06月13日
発行: Markets & Data
ページ情報: 英文 229 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の犬の拡張型心筋症治療薬の市場規模は、予測期間の2025年～2032年に5.01%のCAGRで拡大し、2024年の39億9,000万米ドルから2032年には59億米ドルに成長すると予測されています。世界の犬の拡張型心筋症治療薬市場は、犬用薬剤の進歩、ペットオーナーの意識の向上、犬DCM治療に対する需要の高まりにより、大きな成長を遂げています。

同市場は、診断の進歩や犬、特に大型犬や巨大犬種における心臓病の有病率の上昇とともに、一般市民の意識の高まりにより着実な成長を遂げています。犬のDCMは重篤な心筋疾患であり、主に選択される薬剤クラス別には、ピモベンダンなどの血管拡張薬、利尿薬、血管収縮酵素（ACE）阻害薬などがあり、心拍出量と心機能の改善、体液貯留の解消、心臓の負担軽減に役立ちます。市場の開拓と成長に関しては、犬DCMの研究開発と製品開発が進行中であり、遺伝子治療やより高度な製剤を含む多くの新しい治療オプションが分析され、より優れた、潜在的な疾患修飾療法が生み出されています。犬DCM治療薬の世界市場は、ペットの人間化という大きな現象にも影響を受けています。

さらに、ペットのヒューマニゼーションの動向を監督するために、食品医薬品局（FDA）も新しい治療計画を承認することで支援しています。例えば、2024年4月、ピモメディンチュアブルタブレット、最初のジェネリックピモベンダンは、犬のうっ血性心不全の管理のためにFDAから承認を受けた。これらの薬は心臓の筋収縮を強化し、これらの臓器の血管を広げるのに役立ちます。

当レポートでは、世界の犬の拡張型心筋症（DCM）治療薬市場について調査し、市場の概要とともに、治療アプローチ別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の犬の拡張型心筋症（DCM）治療薬市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
    • 治療アプローチ別
      • 症状管理薬
      • 疾患修飾薬
      • 支持療法剤
    • 投与経路
      • 経口
      • 注射
    • 流通チャネル別
      • 動物病院
      • 獣医クリニック
      • 小売薬局
      • オンライン薬局
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東・アフリカ
    • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
  • 2024年の市場マップ分析

第6章 北米の犬の拡張型心筋症（DCM）治療薬市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
  • 国別市場評価
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の犬の拡張型心筋症（DCM）治療薬市場の見通し、2018年～2032年

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド

第8章 アジア太平洋の犬の拡張型心筋症（DCM）治療薬市場の見通し、2018年～2032年

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第9章 南米の犬の拡張型心筋症（DCM）治療薬市場の見通し、2018年～2032年

  • ブラジル
  • アルゼンチン

第10章 中東・アフリカの犬の拡張型心筋症（DCM）治療薬市場の見通し、2018年～2032年

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

  • 市場の促進要因
  • 市場の課題

第17章 市場動向と発展

第18章 規制の枠組み

  • 規制当局の承認
  • 臨床試験

第19章 特許の情勢

第20章 ケーススタディ

第21章 競合情勢

  • 市場リーダートップ5の競合マトリックス
  • 参入企業トップ5のSWOT分析
  • 市場の主要企業トップ10の情勢
    • Boehringer Ingelheim International GmbH
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Elanco Animal Health Incorporated
    • Vetoquinol group
    • Ceva Sante Animale
    • Bayer AG
    • Dechra Pharmaceuticals PLC
    • Orion Corporation
    • SAVA Vet

第22章 戦略的提言

第23章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 3. Global Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 4. Global Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 5. Global Canine Dilated Cardiomyopathy Drugs Market Share (%), By Region, 2018-2032F
  • Figure 6. North America Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 7. North America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 8. North America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 9. North America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 10. North America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Country, 2018-2032F
  • Figure 11. United States Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 12. United States Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 13. United States Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 14. United States Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 15. Canada Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. Canada Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 17. Canada Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 18. Canada Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 19. Mexico Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 20. Mexico Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 21. Mexico Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 22. Mexico Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Europe Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Europe Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 25. Europe Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 26. Europe Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Europe Canine Dilated Cardiomyopathy Drugs Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Germany Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 30. Germany Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 31. Germany Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 32. France Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 33. France Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 34. France Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 35. France Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 36. Italy Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 37. Italy Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 38. Italy Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 39. Italy Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 40. United Kingdom Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. United Kingdom Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 42. United Kingdom Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 43. United Kingdom Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Russia Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Russia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 46. Russia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 47. Russia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 48. Netherlands Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 49. Netherlands Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 50. Netherlands Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 51. Netherlands Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Spain Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Spain Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 54. Spain Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 55. Spain Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 56. Turkey Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 57. Turkey Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 58. Turkey Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 59. Turkey Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 60. Poland Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 61. Poland Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 62. Poland Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 63. Poland Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. South America Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. South America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 66. South America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 67. South America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 68. South America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Country, 2018-2032F
  • Figure 69. Brazil Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Brazil Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 71. Brazil Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 72. Brazil Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 73. Argentina Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 74. Argentina Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 75. Argentina Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 76. Argentina Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 77. Asia-Pacific Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 78. Asia-Pacific Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 79. Asia-Pacific Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 80. Asia-Pacific Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 81. Asia-Pacific Canine Dilated Cardiomyopathy Drugs Market Share (%), By Country, 2018-2032F
  • Figure 82. India Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. India Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 84. India Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 85. India Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 86. China Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 87. China Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 88. China Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 89. China Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. Japan Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Japan Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 92. Japan Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 93. Japan Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 94. Australia Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. Australia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 96. Australia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 97. Australia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 98. Vietnam Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 99. Vietnam Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 100. Vietnam Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 101. Vietnam Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 102. South Korea Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 103. South Korea Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 104. South Korea Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 105. South Korea Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 106. Indonesia Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. Indonesia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 108. Indonesia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 109. Indonesia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. Philippines Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. Philippines Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 112. Philippines Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 113. Philippines Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 114. Middle East & Africa Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 115. Middle East & Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 116. Middle East & Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 117. Middle East & Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 118. Middle East & Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 120. Saudi Arabia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 121. Saudi Arabia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 122. Saudi Arabia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 123. UAE Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 124. UAE Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 125. UAE Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 126. UAE Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 127. South Africa Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 128. South Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
  • Figure 129. South Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 130. South Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 131. By Therapeutic Approach Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 132. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
目次
Product Code: MX13331

Global canine dilated cardiomyopathy drugs market is projected to witness a CAGR of 5.01% during the forecast period 2025-2032, growing from USD 3.99 billion in 2024 to USD 5.90 billion in 2032. The global canine dilated cardiomyopathy drugs market is experiencing significant growth due to advancements in canine drugs, increased awareness among pet owners, and growing demand for canine DCM treatment.

The market is witnessing a steady increase due to a rise in public awareness, along with advancements in diagnosis and an increasing prevalence of heart disease in dogs, particularly in large and giant breeds. Canine DCM is a severe heart muscle disease, and the main selected drug classes include vasodilators such as pimobendan, diuretics, and angiotension-converting enzyme (ACE) inhibitors to help improve cardiac output and function, relieve fluid retention, and reduce workload on the heart. With regards to the development and growth of the market, research and product development in Canine DCM is ongoing, and the market is analyzing many new treatment options, including genetic therapies and more advanced formulations to produce better and potentially disease-modifying therapies. The market for canine DCM drugs globally is also impacted by a larger phenomenon, which is pet humanization.

Additionally, to oversee the growing pet humanization trends Food and Drug Administration (FDA) also supports by giving approvals of new treatment plans. For instance, in April 2024, Pimomedin chewable tablets, the first generic pimobendane, received approval from the FDA for the management of congestive heart failure in dogs. These drugs help to strengthen the muscular contraction of the heart and widen the blood vessels in these organs.

Rising Prevalence of Canine DCM Drugs Drives Global Market Demand

Medical professionals in veterinary medicine face a rising need for specialized drugs to treat canine dilated cardiomyopathy because it represents a major veterinary medical problem. Dogs of large and giant breeds face the highest DCM risk because the disease primarily affects Dobermans, Great Danes, and Irish Wolfhounds. The condition's appearance in various dog breeds lately has led to inquiries about how diet choices, especially boutique and grain-free options that lack taurine, could be related to the problem. Modern diagnostic tools that include echocardiography and Holter monitoring provide better means to identify this condition. The general increase in pet ownership, along with growing public knowledge brought by social media platforms, together with obvious clinical symptoms of lethargy and coughing, and labored breathing, has led to an increasing number of reported cases of canine DCM.

For instance, in July 2024, Elanco Animal Health Incorporated announced a partnership with The Veterinary Cooperative (TVC) for an extensive portfolio of innovative products and practice resources and enhance the quality of care provided by TVC members.

The Rising Focus on Canine DCM Drug Innovation Drives Market Growth

The global market is undergoing substantial expansion owing to mounting pet populations and better awareness about dog cardiovascular conditions, along with veterinary medical advancements. Multiple pharmaceutical firms, along with research organizations, dedicate their resources to developing new medications that will enhance dog survival and quality of life by addressing DCM as a primary heart failure trigger among large canine breeds. The market surge stems from an increasing requirement for specialized pet care services and the establishment of strategic research partnerships between veterinary health organizations and expanding awareness about pets' benefits on human psychological health. Veterinary pharmaceutical and pet care industry stakeholders can find valuable information about emerging drug developments, together with market dynamics and economic effects of canine DCM treatments.

For instance, in February 2025, Mars Petcare's Waltham Petcare Science Institute launched a program to understand the human-animal bond shared benefits on National Love Your Pet Day. This study also aims to increase awareness of the role played by pets in maintaining owners' mental well-being.

Advances in Veterinary Medicine Drive the Canine Dilated Cardiomyopathy Drugs Market Demand

Progress in veterinary medicine has exponentially enhanced the ability to diagnose and treat canine DCM, increasing demand for canine drug products. Technology advancements such as high-resolution ECG and portable Holter monitor permit earlier diagnosis and continuous monitoring of the heart. Therapeutically, the development of novel drug formulation and delivery methods has improved efficacy and ease of use. Concerning ongoing treatment, telemedicine and digital monitoring systems have helped follow-up care more frequently and constantly than before, facilitating long-term disease management and reinforcing the critical role of veterinary medicine in DCM.

Additionally, to support the digitalization system in September 2023, iRhythm Technologies, Inc. introduced its next-generation Zio monitor and enhanced Zio long-term continuous monitoring (LTCM) service to enhance the cardiac monitoring experience for patients and healthcare providers, together with new service enhancements. It is based on an AI algorithm that supports the capture and analysis of ECG data.

Therapeutic Drugs Hold the Largest Canine Dilated Cardiomyopathy Drugs Market Share

Therapeutic drugs hold the largest market share as they are necessary to manage life-threatening diseases by controlling symptoms and disease progression. These include positive inotropes such as pimobendane, ACE inhibitors, beta-blockers and diuretics, which form the basis of any treatment protocol to improve cardiac function, decrease fluid retention, and ultimately improve the quality of life of affected dogs. With the increasing diagnostic rate of DCM being partly due to increased awareness and the ability to perform advanced veterinary diagnostics, the need for well-established drug therapies is likely to increase.

For instance, in May 2024, UpCard-CA1 drugs, the first torsemide oral solution for dogs, received approval from the FDA, which is a concurrent therapy to be used for pulmonary edema in dogs with congestive heart failure secondary to myxomatous mitral valve disease (MMVD).

North America Dominates the Global Canine DCM Drugs Market Size

The North America region holds the primary position in the canine dilated cardiomyopathy (DCM) drugs market, owing to elevated veterinary care expenditures, established medical facilities, and innovative pharmaceutical research. The rising trend of humanizing pets leads to an increase in market demand owing as numerous pet owners select specialized treatments for conditions such as DCM. Through advanced veterinary systems, which include specialized hospitals and board-certified cardiologists, the diagnosis and treatment of veterinary patients are supported. Animal health companies that lead the industry dedicate significant resources to research and development to develop innovative cardiac medications. The combined effects of these elements result in North America becoming the main market for DCM drug sales worldwide.

Additionally, to oversee the growing pet humanization trends in this region organization also provides pet health insurance across Canada and the United States. For instance, in April 2025, the National American Pet Health Insurance Association, Inc. (NAPHIA) released its survey result, which shows that about 7.03 million pets were insured in North America at the end of 2024.

Impact of U.S. Tariffs on Global Canine Dilated Cardiomyopathy Drugs Market

US tariffs have the potential to affect the global canine dilated cardiomyopathy (DCM) drugs market by raising costs and impacting different supply chains. Most veterinary pharmaceuticals (as well as DCM drugs) are produced using foreign active pharmaceutical ingredients (APIs) and resources. Tariffs imposed on imported APIs increase the production costs of the manufacturer, that usually passed on to the veterinary clinics and pet owners, resulting in higher prices for the DCM treatment drugs. Some pet owners may delay treatment or not have the ability to afford the treatment, which could negatively impact animal welfare and demand for the products. Tariffs may also force companies to search for alternative suppliers, which may take time to locate or produce a delay or disruption in the product to the marketplace due to disrupted supply chains.

Key Players Landscape and Outlook

Continuous innovation and constant change promote the global canine dilated cardiomyopathy drugs market. Companies are investing in research and development to target new canine heart diseases with more effective treatments. Companies intend to improve drug product development, treatment options, and the safety and efficacy of medication used in the treatment of canine DCM. Many drug companies are strategically aligning their product development and market strategies with greater demand around a companion animal emphasis of pet health and wellness. The presence of an additional online veterinary pharmacy and tele-veterinary service will also change how treatment is accessed in the current market and beyond.

For instance, in November 2024, Boehringer Ingelheim International GmbH introduced VETMEDIN Solution approved by Food and Drugs Administration (FDA) to manage congestive heart failure in dogs to increase the survival time and provide quality of life in dogs who are affected by MMVD (myxomatous mitral valve disease) or DCM (dilated cardiomyopathy).

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Therapeutic Approach
      • 5.2.1.1. Symptom Management Drugs
        • 5.2.1.1.1. Diuretics
        • 5.2.1.1.2. Vasodilators
      • 5.2.1.2. Disease-Modifying Drugs
        • 5.2.1.2.1. ACE Inhibitors
        • 5.2.1.2.2. Angiotensin II Receptor Blockers (ARBs)
        • 5.2.1.2.3. Pimobendan
      • 5.2.1.3. Supportive Care Agents
        • 5.2.1.3.1. Anti-Arrhythmics
        • 5.2.1.3.2. Cardiac Glycosides
    • 5.2.2. By Route of Administration
      • 5.2.2.1. Oral
      • 5.2.2.2. Injectable
    • 5.2.3. By Distribution Channel
      • 5.2.3.1. Veterinary Hospitals
      • 5.2.3.2. Veterinary Clinics
      • 5.2.3.3. Retail Pharmacies
      • 5.2.3.4. Online Pharmacies
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia-Pacific
      • 5.2.4.4. South America
      • 5.2.4.5. Middle East and Africa
    • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Therapeutic Approach
    • 5.3.2. By Route of Administration
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Therapeutic Approach
      • 6.2.1.1. Symptom Management Drugs
        • 6.2.1.1.1. Diuretics
        • 6.2.1.1.2. Vasodilators
      • 6.2.1.2. Disease-Modifying Drugs
        • 6.2.1.2.1. ACE Inhibitors
        • 6.2.1.2.2. Angiotensin II Receptor Blockers (ARBs)
        • 6.2.1.2.3. Pimobendan
      • 6.2.1.3. Supportive Care Agents
        • 6.2.1.3.1. Anti-Arrhythmics
        • 6.2.1.3.2. Cardiac Glycosides
    • 6.2.2. By Route of Administration
      • 6.2.2.1. Oral
      • 6.2.2.2. Injectable
    • 6.2.3. By Distribution Channel
      • 6.2.3.1. Veterinary Hospitals
      • 6.2.3.2. Veterinary Clinics
      • 6.2.3.3. Retail Pharmacies
      • 6.2.3.4. Online Pharmacies
    • 6.2.4. By Country Share
      • 6.2.4.1. United States
      • 6.2.4.2. Canada
      • 6.2.4.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Therapeutic Approach
          • 6.3.1.2.1.1. Symptom Management Drugs
          • 6.3.1.2.1.1.1. Diuretics
          • 6.3.1.2.1.1.2. Vasodilators
          • 6.3.1.2.1.2. Disease-Modifying Drugs
          • 6.3.1.2.1.2.1. ACE Inhibitors
          • 6.3.1.2.1.2.2. Angiotensin II Receptor Blockers (ARBs)
          • 6.3.1.2.1.2.3. Pimobendan
          • 6.3.1.2.1.3. Supportive Care Agents
          • 6.3.1.2.1.3.1. Anti-Arrhythmics
          • 6.3.1.2.1.3.2. Cardiac Glycosides
        • 6.3.1.2.2. By Route of Administration
          • 6.3.1.2.2.1. Oral
          • 6.3.1.2.2.2. Injectable
        • 6.3.1.2.3. By Distribution Channel
          • 6.3.1.2.3.1. Veterinary Hospitals
          • 6.3.1.2.3.2. Veterinary Clinics
          • 6.3.1.2.3.3. Retail Pharmacies
          • 6.3.1.2.3.4. Online Pharmacies
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework

  • 18.1. Regulatory Approvals
  • 18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Boehringer Ingelheim International GmbH
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. Zoetis Inc.
    • 21.3.3. Merck & Co., Inc.
    • 21.3.4. Elanco Animal Health Incorporated
    • 21.3.5. Vetoquinol group
    • 21.3.6. Ceva Sante Animale
    • 21.3.7. Bayer AG
    • 21.3.8. Dechra Pharmaceuticals PLC
    • 21.3.9. Orion Corporation
    • 21.3.10. SAVA Vet

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer